Related Experiment Video
Updated: Mar 22, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.2K
Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness
Vishal Ahuja1, Chia-Hung Chou2
1Cox School of Business, Southern Methodist University, PO Box 750333, Dallas, TX, 75275, USA. vahuja@smu.edu.
Current Diabetes Reports
|April 15, 2016
Summary
Novel type 2 diabetes drugs, including DPP-4 inhibitors and GLP-1 receptor agonists, show promise but require more long-term safety and effectiveness data. Thiazolidinediones usage declined after safety concerns emerged.
Area of Science:
- Endocrinology
- Pharmacology
- Public Health
Background:
- Recent years have seen a significant increase in type 2 diabetes therapies.
- Novel antidiabetic agents' benefits and risks require thorough evaluation.
Purpose of the Study:
- To review and synthesize literature on the uptake, efficacy, safety, and cost-effectiveness of new antidiabetic medications.
- Focus on thiazolidinediones (TZDs), dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists.
Main Methods:
- Literature review and synthesis of existing studies.
- Analysis of usage trends, efficacy, safety, and cost-effectiveness data.
- Focus on three recently introduced drug classes.
Main Results:
- Thiazolidinedione use decreased following cardiovascular risk warnings.
- DPP-4 inhibitors and GLP-1 receptor agonists gained market share for glycemic control.
- DPP-4 inhibitors, particularly sitagliptin, were most prescribed due to cost, safety, oral administration, and weight neutrality.
Conclusions:
- Usage trends correlate with drug efficacy and safety profiles.
- Evidence on comparative effectiveness, safety, and cost of novel agents is limited.
- Further long-term studies are essential for comprehensive understanding.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
912
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
912
01:06Oral Hypoglycemic Agents: Glinides
926
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
926
01:15Diabetes: Management and Pharmacotherapy
1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.6K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.6K
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K